Physician profile
Daniel R Smith
NPI 1528562865
$908.46
in general payments reported to CMS, 2019-2025
14 companies · $872 in 2025
The $872 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.69 · 2024: $16.34 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $207.38 | 2025 | |
| Janssen Pharmaceuticals, INC | $178.40 | 2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $127.15 | 2025 | |
| Axsome Therapeutics, INC. | $124.69 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.86 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $46.05 | 2025 | Rexulti |
| Lundbeck LLC | $39.51 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $29.51 | 2025 | Uzedy |
| Nalu Medical, INC. | $19.69 | 2022 | |
| Lilly USA, LLC | $18.52 | 2025 | Zepbound |
| Alkermes, INC. | $17.23 | 2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $16.34 | 2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2025 | Trintellix |
| Corium, LLC | $6.32 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.